Pliant Therapeutics, Inc.

PLRXNASDAQHealthcare● Active

$1.15

+$0.00(+0.00%)

Market Cap$71208230

P/E Ratio—

52W High$1.95

52W Low$1.09

Avg Volume529K

Open$1.14

Beta1.21

Forecast Market Cap PE Ratio

Pliant Therapeutics, Inc.（PLRX）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

plrx · 股价预测 · 16 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 16 位华尔街分析师

Buy

16 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 16 · 买入占比: 50.0%

12 个月目标价

High

$3.00

Consensus

$3.00

+160.9% upside

Low

$3.00

Median: $3 · Last Close: $1.15

Pliant Therapeutics, Inc.（PLRX）的分析师共识为 Buy，基于过去 3 个月内 16 位华尔街分析师的评级。PLRX 的 12 个月平均目标价为 $3.00，相对当前价 $1.15 代表 +160.9% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

Low Activity

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-10	$1.13	↓ 1.46%	$1.12	$1.14

1-day model range: $1.12–$1.14. Peak: $1.14 (-1.46%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$1	—	$1	-31.2%
2028	$1	—	$1	-42.0%
2029	$1	—	$1	-46.5%
2030	$1	—	$1	-48.6%
2031	$1	—	$1	-49.6%

Confidence:Very Low

⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)45.5

MACDBEARISH

Moving Averages · PLRX · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$1.16SELL

MA 10$1.20SELL

MA 20$1.19SELL

MA 50$1.24SELL

MA 100$1.25SELL

MA 200$1.38SELL

Current $PLRX · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$1.17SELL

EMA 10$1.18SELL

EMA 20$1.20SELL

EMA 50$1.22SELL

EMA 100$1.27SELL

EMA 200$1.35SELL

Current $PLRX · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2026-03-13	Canaccord Genuity	Maintains	Hold→Hold
2026-03-12	Piper Sandler	Maintains	Overweight→Overweight
2025-11-07	RBC Capital	Maintains	Sector Perform→Sector Perform
2025-10-10	JP Morgan	Downgrade ↓	Neutral→Underweight
2025-08-08	Piper Sandler	Maintains	Overweight→Overweight
2025-03-18	HC Wainwright & Co.	Maintains	Neutral→Neutral
2025-03-04	HC Wainwright & Co.	Maintains	Neutral→Neutral
2025-03-04	Citigroup	Maintains	Neutral→Neutral
2025-03-04	Needham	Downgrade ↓	Buy→Hold
2025-03-04	RBC Capital	Maintains	Sector Perform→Sector Perform

Canaccord Genuity2026-03-13

Maintains

Hold→Hold

Piper Sandler2026-03-12

Maintains

Overweight→Overweight

RBC Capital2025-11-07

Maintains

Sector Perform→Sector Perform

JP Morgan2025-10-10

Downgrade ↓

Neutral→Underweight

Piper Sandler2025-08-08

Maintains

Overweight→Overweight

HC Wainwright & Co.2025-03-18

Maintains

Neutral→Neutral

HC Wainwright & Co.2025-03-04

Maintains

Neutral→Neutral

Citigroup2025-03-04

Maintains

Neutral→Neutral

Needham2025-03-04

Downgrade ↓

Buy→Hold

RBC Capital2025-03-04

Maintains

Sector Perform→Sector Perform

Wall Street analysts have recently issued updated ratings on Pliant Therapeutics, Inc. (PLRX) stock. Of the recent 94 rating actions, 0 were upgrades and 9 were downgrades. 16 analysts currently cover PLRX.

分析师推荐趋势

Buy ratings2 → 1↓ 1

Hold ratings7 → 1↓ 6

Sell ratings0 → 0

PLRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$3M

↓ 83.3% YoY

Revenue Next Year

$5M

↑ 100.0% YoY

EPS This Year

$-1.41

EPS Next Year

$-1.05

↓ 25.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PLRX EPS of $-1.41 for the current fiscal year, based on estimates from 4 analysts. The PLRX revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

PLRX 股价预测由两类独立数据源支撑：来自 16 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PLRX 的共识目标价为 $3.00（+160.9% 上行空间），分析师共识为 Buy。

PLRX 的短期预测（明日）为 $1.13（-1.46%）。 PLRX 对 2030 年的预测区间为 $1–$1。

Pliant Therapeutics, Inc. 在 NASDAQ 上市，代码 PLRX。PLRX 在 2027 年的整体展望偏积极，在覆盖分析师中约 50% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

PLRX 预测 · 8 个问题

根据 16 位华尔街分析师，PLRX 的 12 个月平均目标价为 $3.00，最高 $3.00、最低 $3.00。若有图表，中位目标价可在上方查看。相对当前价 $1.15，隐含约 +160.9% 的上行空间。

PLRX 目标价PLRX 分析师目标价PLRX 12个月目标价目标价 PLRX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.